Skip to main content
SpringerLink
Log in

Empagliflozin

Euglycemic diabetic ketoacidosis: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Secinaro E, et al. SGLT2-inhibitors and euglycemic diabetic ketoacidosis in COVID-19 pandemic era: a case report. Acta Diabetologica 59: 1391-1394, No. 10, 19 Jun 2022. Available from: URL: http://doi.org/10.1007/s00592-022-01909-9

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Empagliflozin. Reactions Weekly 1924, 205 (2022). https://doi.org/10.1007/s40278-022-23558-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-23558-y

Search

Navigation